FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

|--|

Г

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

1. Name and Address of Reporting Person* GILEAD SCIENCES, INC.						rna	me and Ticl Therap	eut	<u>ics, In</u>	<u>c.</u> [KYTX		S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner								
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/12/2024										Officer (g below)	ive title		Other (sp below)	pecify		
333 LAK	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indiv	ridual or Joir Form filed		٠,		able Line)						
(Street)																X Form filed by One Reporting Person Form filed by More than One Reporting Person					
FOSTER CITY CA 94404					Rule 10b5-1(c) Transaction Indication																
(City)	(City) (State) (Zip)						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3) 2. Trans Date (Month/l					ction ay/Year)	2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.				rities Acqui ed Of (D) (In			5. Amount Securities Beneficially Following	Form:		Direct Indirect Etr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A)	(A) or (D) Price		Reported Transaction(s) (Instr. 3 and 4)									
Common	Stock	/2024			C		3,216	5,119 A		(1)	3,216,119(2)			D							
Common Stock 02/12									P		910,0	000 A		\$22	4,126,119		D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code	saction (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisal Expiration Date (Month/Day/Year			7. Title and Amount o Securities Underlying Derivative Security (Ir 3 and 4)		rlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Dat Exe	e ercisable		opiration ate	Title		unt or ber of es		(Instr. 4)					
Series A-2 Convertible Preferred Stock	(1)	02/12/2024		С			6,890,744		(1)		(1)	Common Stock	1,51	4,083(2)	\$0	0		D			
Series B Convertible Preferred Stock	(1)	02/12/2024		С	С		7,746,139		(1)		(1)	Common Stock 1,702,036 ⁽²⁾		\$0	0		D				

Explanation of Responses:

- 1. The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.
- 2. Reflects a 1-for-4.5511 reverse stock split, which became effective on January 30, 2024.

Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson

02/13/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.